Drug Trial Radar · NCT05798520
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Jul 25, 2023
Primary completion
Feb 10, 2026
Study completion Feb 10, 2026
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Apr 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study. In Part 1, one set of participants will take either BIIB091 or diroximel fumarate (DRF). In Part 2, a different set of participants will take either a combination of BIIB091 and DRF or DRF alone. The goal of the study is to learn more about the safety of BIIB091 and to compare the effects of the study drug when taken alone or together with DRF. The main question researchers are trying to answer are: * How many participants have new or worsening medical problems (adverse events) after taking BIIB091 or DRF? * How many new areas of inflammation occur in the brain after treatment with BIIB091 and DRF? Researchers will use magnetic resonance imaging (MRI) scans to compare images of the brain before and after treatment. They will also explore the effect of BIIB091 and DRF on the heart using electrocardiograms (ECGs). The study will be done as follows: * After screening, participants who joined Part 1 will be randomly assigned to receive either a high or low dose of BIIB091, or the standard dose of DRF. * The results of Part 1 will be used to choose the best dose of BIIB091 to use in Part 2. * Participants who join Part 2 will be randomly assigned to receive either a standard dose of DRF, a combo of BIIB091 and the standard dose of DRF, or a combo of BIIB91 with a low dose of DRF. * Neither the researchers nor the participants will know which drug or dose the participants will receive in either part of the study. * The treatment period will last 48 weeks in each part of the study. Participants will take the drugs by mouth 2 times a day. * Each part will also have a follow-up safety period that lasts up to 2 weeks. * In total, participants in each part will have 20 study visits, or more if they have a relapse. The total study duration for participants will be up to 54 weeks.
Conditions
- Relapsing Forms of Multiple Sclerosis
Interventions
BIIB091Drug
Administered as specified in the treatment arm.
DRFDrug
Administered as specified in the treatment arm.
PlaceboDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Adverse Events (AEs)Time frame: Day 1 up to Week 50
- Part 1: Number of Participants With Serious Adverse Events (SAEs)Time frame: From signing the informed consent form (ICF) to Week 50
- Part 2: Cumulative Number of New T1 Gadolinium-Enhancing (GdE) LesionsTime frame: Week 8 to Week 16
Locations
77 sites in 10 countries. Site status is shown where the registry gives one.
HonorHealth Neurology
Scottsdale, Arizona
Alta Bates Summit Medical Center
Berkeley, California
University of California at Irvine Medical Center
Orange, California
University of Colorado School of Medic
Aurora, Colorado
University of Miami Miller School of Medicine
Miami, Florida
University of South Florida
Tampa, Florida
Vero Beach Neurology and Research Institute
Vero Beach, Florida
Fort Wayne Neurological Center
Fort Wayne, Indiana
University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas
International Neurorehabilitation Institute
Lutherville, Maryland
Washington University
St Louis, Missouri
Holy Name
Teaneck, New Jersey
University of New Mexico
Albuquerque, New Mexico
South Shore Neurologic Associates, P.C.
Patchogue, New York
Wake Forest University - School of Medicine - Central
Winston-Salem, North Carolina
University of Cincinnati Physicians Company
Cincinnati, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio
The Boster Center for Multiple Sclerosis
Columbus, Ohio
Neurology Clinic, PC
Cordova, Tennessee
Vanderbilt MS Center
Nashville, Tennessee
The University of Texas Health Science Center San Antonio
San Antonio, Texas
University of Wisconsin Hospital and Clinics
Madison, Wisconsin
The Medical College of Wisconsin
Milwaukee, Wisconsin
'MHAT Avis - Medica' OOD
Pleven, Bulgaria
UMHAT 'Dr. Georgi Stranski', EAD
Pleven, Bulgaria
UMHAT 'Sv. Georgi', EAD
Plovdiv, Bulgaria
MHATNP 'Sv.Naum', EAD
Sofia, Bulgaria
University First MHAT-Sofia, 'St. Joan Krastitel' EAD
Sofia, Bulgaria
Acibadem City Clinic Tokuda University Hospital Ead
Sofia, Bulgaria
DCC Neoclinic EAD
Sofia, Bulgaria
UMHAT "Sv. Ivan Rilski", EAD
Sofia, Bulgaria
Diagnostic Consultation Center CONVEX EOOD
Sofia, Bulgaria
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
Fakultni nemocnice Hradec Kralove
Hradec Králové, Czechia
Nemocnice Jihlava p.o.
Jihlava, Czechia
Fakultni Thomayerova nemocnice
Praha 4-Krc, Czechia
Krajska zdravotni a.s. - Nemocnice Teplice o.z.
Teplice, Czechia
Universitaetsklinikum Carl Gustav Carus TU Dresden
Dresden, Germany
Studienzentrum fur Neurologie und Psychiatrie
Böblingen, Baden-Wurttemberg, Germany
Klinikum Bayreuth GmbH- Hohe Warte
Bayreuth, Bavaria, Germany
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.